Werewolf Therapeutics Engages at Kidney Cancer Research Summit
WATERTOWN, Mass. — Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), a forward-thinking biopharmaceutical company, is making strides in its mission to revolutionize cancer treatment through conditionally activated therapeutics. This approach aims to empower the body’s immune system to combat cancer and other related immune disorders effectively. Recently, Dr. Randi Isaacs, the Chief Medical Officer of Werewolf, announced her participation in the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit. This exciting event will take place over two days, where cutting-edge discussions on kidney cancer and its treatments will unfold.
Innovative Strategies and Early Findings
Dr. Isaacs is set to present insights into Werewolf’s groundbreaking methodology centered around conditionally activated cytokines. These molecules are designed to focus immune activation directly in tumors, a potential game-changer in oncological therapies. A key highlight of her presentation will be the early clinical results for WTX-124, a specially engineered IL-2 INDUKINE molecule. While traditional high-dose IL-2 therapy has shown efficacy for renal cell carcinoma (RCC), its widespread use has been curtailed due to severe side effects. Dr. Isaacs emphasizes how WTX-124 endeavors to enhance therapeutic benefits while minimizing adverse systemic reactions.
Presentation Details
The presentation is scheduled for Friday, where Dr. Isaacs will elaborate on "Unmasking the Potential of Conditionally-Activated Cytokines: Lessons Learned from the Early Clinical Development of WTX-124." This session is part of the Biotech Showcase series, providing insights into novel therapeutic avenues that could redefine treatment paradigms for kidney cancer.
Full Moon Moment and Ongoing Trials
In conjunction with the summit, Werewolf is running the “Full Moon Moment” campaign — an initiative designed to raise awareness about its national trials. The campaign is particularly focused on the WTX-124 IL-2 INDUKINE molecule, which is currently open for patient enrollment. This effort serves not just as an outreach program but also as a beacon of hope for patients suffering from advanced or metastatic RCC and other solid tumors. The campaign has already reported multiple positive responses, heralding the potential end of an extended remission for patients, such as one individual with cutaneous squamous cell carcinoma who has exceeded a year in remission.
Significance of INDUKINE™ Molecules
The term “Full Moon Moment” symbolizes the activation of these INDUKINE™ molecules, revealing their tumor-fighting capabilities specifically within the tumor microenvironment. The innovative nature of Werewolf’s therapies manifests their ability to remain dormant in non-cancerous tissue, activating only when necessary. This selective activation could revolutionize treatment efficacy, offering patients a more targeted therapeutic experience.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is at the forefront of developing cutting-edge biopharmaceutical interventions aimed at harnessing the body’s immune response for cancer treatment. Through its proprietary PREDATOR platform, the company is committed to crafting and implementing conditionally activated molecules. These developments hold the promise of bridging gaps identified in standard immune therapies. Key candidates under development include WTX-124 and WTX-330, both of which are conditionally activated Interleukin molecules expected to address various solid tumors and Non-Hodgkin Lymphoma. The focused advancement of these candidates champions a new horizon in immunotherapy.
Contact Information
For further inquiries, Werewolf encourages stakeholders to reach out through the following contacts:
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
Frequently Asked Questions
What is Werewolf Therapeutics known for?
Werewolf Therapeutics specializes in the development of biopharmaceuticals aimed at harnessing the immune system for cancer treatment.
What are the key products developed by Werewolf?
The primary therapeutic candidates include WTX-124 and WTX-330, designed to selectively activate immune responses in tumors.
Who will present at the Kidney Cancer Summit?
Dr. Randi Isaacs, the CMO of Werewolf, will present at the summit, focusing on innovative cancer treatment strategies.
What does the "Full Moon Moment" campaign entail?
This initiative promotes awareness of ongoing clinical trials related to innovative therapies, encouraging patient participation.
How can I contact Werewolf Therapeutics?
For inquiries, individuals can reach out to the investor, media, or company contacts listed in the article.
